Glycomed Downsizes In Faces Of Competition

Glycomed Inc. is trimming its sails, dropping its Astenose heparinoid compound and cutting back from three simultaneous development programs to two.

An NDA filing is still planned for Galardin, which is in Phase III trials for corneal ulcers. About 490 patients have been enrolled, and the company plans to complete enrollment at the end of June with 540 patients. Once the data are analyzed, the company hopes to file for marketing approval in 1995...